drugset

drugset / Trial / NCT07369986

Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial Cancer

NCT07369986 ↗

Phase 2 Not yet recruiting 30 enrolled Women's Hospital School Of Medicine Zhejiang University

NaSingle-groupOpen-labelTreatment

Summary

Efficacy evaluate of iparomlimab and tuvonralimab (a PD-1/CTLA-4 bispecific antibody) in patients with surgically resectable dMMR endometrial cancer.

Timeline

Start: 2026-03-01
Primary completion: 2027-12-31
Completion: 2028-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Iparomlimab and Tuvonralimab	Unknown	—	—

Indications